Tandem Diabetes Care announces release of t:flex Insulin Pump

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today announced that it is now taking orders for the t:flex™ Insulin Pump, with shipments planned to begin in June. The 480-unit t:flex Pump, cleared by the U.S. Food and Drug Administration in January 2015, is the largest capacity insulin pump currently offered in the United States.

"Two-thirds of the healthcare providers we interviewed prior to developing the t:flex Pump cited limited capacity as the number one barrier to pump adoption for people with type 2 diabetes who use insulin," said Kim Blickenstaff, President and CEO of Tandem Diabetes Care. "We believe the t:flex Pump addresses an important unmet need in the diabetes community, with its 480-unit reservoir and 60-unit maximum bolus, and we are proud to offer this option for people with greater insulin needs."

The t:flex Pump is designed for people who require more than 80 units of U-100 insulin per day, such as teenagers with type 1 diabetes and many people with type 2 diabetes. For people with greater insulin needs, the pump offers the benefits of pump therapy without the frequent reservoir changes required by 200- and 300-unit pumps. It incorporates the same slim design, advanced Micro-Delivery® technology, and simple-to-use touch-screen interface as the t:slim Insulin Pump, rated #1 by pump users for two years in a row.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes medication shows promise in reducing alcohol use